Russia to provide COVID-19 drug Avifavir to 17 more countries
MOSCOW (RUSSIA) – Russia’s sovereign wealth fund and its partner Chemrar will provide the COVID-19 drug Avifavir to 17 additional countries, on Thursday.
The Russian health ministry gave approval to Avifavir in May and is based on Favipiravir. It was developed in Japan and is used widely as the basis for viral treatments.
The Russian Direct Investment Fund (RDIF) said in a statement that clinical trials in Japan and Russia have confirmed the effectiveness of those drugs.
Russia is trying hard to be in the forefront in the race against the virus. Its COVID-19 tests have already expanded and has roped in several international deals for Sputnik-V vaccine’s supplies.
Avifavir has already been handed over to Belarus, Bolivia, Kazakhstan, Kyrgyzstan, Turkmenistan and Uzbekistan. The RDIF said it would now be sent to Argentina, Bulgaria, Brazil, Chile, Colombia, Ecuador, El Salvador, Honduras, Kuwait, Panama, Paraguay, Saudi Arabia, Serbia, Slovakia, South Africa, the UAE and Uruguay.
Last week Russia gave approval for R-Pharm’s Coronavir treatment for outpatients, who had mild to moderate COVID-19 infections. The company said the antiviral drug could be provided to pharmacies soon this week.
The RDIF said favipiravir-based drugs are three to four times cheaper when compared to remdesivir, another COVID-19 treatment.